Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma.

Trial Profile

Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2011

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SYMBIOSE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Feb 2011 Planned end date changed from Jul 2011 to Aug 2011 as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Planned number of patients changed from 800 to 382 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top